AstraZeneca completes Zegfrovy license agreement
Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 02, 2026
The completion of the licensing deal strengthens AstraZeneca's oncology portfolio, potentially boosting future revenue from Sunvozertinib sales. Dizal receives significant upfront and milestone payments, improving its financial position, while AstraZeneca's stock remained flat, reflecting the deal's expected nature.
AstraZeneca announced the completion of its exclusive global license agreement with Dizal Pharmaceutical for Sunvozertinib (sunvozertinib), an oral EGFR inhibitor for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Under the agreement, AstraZeneca acquires worldwide rights to develop and commercialize Sunvozertinib. AstraZeneca will pay Dizal an upfront payment of $600 million, plus up to $900 million in development, regulatory, and sales milestones, and tiered royalties on global sales. Sunvozertinib is already approved in the US and China for second-line treatment and is available in China; AstraZeneca plans to launch in the US in Q4 2026. A supplemental New Drug Application for first-line use has been accepted by the FDA and submitted to China's CDE, both granting Breakthrough Therapy Designation. The transaction does not affect AstraZeneca's 2026 financial guidance.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard